Company advances manufacturing scale-up, regulatory testing and preclinical work supporting its planned FDA 510(k) submission in the first quarter of 2027. Multiple scaled-up batches of CXU™ material met predefined specifications, supporting both regulatory testing and future commercial production. RENO, Nev., Oct. 06, 2026 (GLOBE NEWSWIRE) — Conexeu Sciences Inc. (Nasdaq: CNXU) (“Conexeu” or the…
A new global analysis has highlighted the role of Epstein-Barr virus in cancer, but infection with the common virus does not mean that a person will develop cancer
At least seven people have died following a confirmed Yellow Fever outbreak in the Sissala East Municipality of the Upper West Region, with children and young people reportedly among the worst…
GENEVA — Russian authorities told the World Health Organization (WHO) on Tuesday that it has no cases of plague in the city of Irkutsk in Siberia, where a laboratory worker at a plague research…
(RTTNews) - HeartSciences (HSCS) said it received FDA 510(k) clearance for its MyoVista wavECG device, advancing the company's efforts to commercialize its artificial intelligence (AI)-enabled ECG…
